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Q  Does niacin decrease  
cardiovascular morbidity and 
mortality in CVD patients?
 no. Niacin doesn’t reduce cardio- 
 vascular disease (CVD) morbidity 
or mortality in patients with established 
disease (strength of recommendation 
[SOR]: A, meta-analyses of randomized 
controlled trials [RCTs] and subsequent 
large RCTs).
Niacin may be considered as mono-
therapy for patients intolerant of statins 
(SOR: B, one well-done RCT). 
Evidence summary
Before the statin era, the Coronary Drug Proj-
ect RCT (8341 patients) showed that niacin 
monotherapy in patients with definite elec-
trocardiographic evidence of previous myo-
cardial infarction (MI) reduced nonfatal MI 
to 8.9% compared with 12.2% for placebo 
(P=.002).1 (See TABLE.1-4) It also decreased 
long-term mortality by 11% compared with 
placebo (P=.0004).5
Adverse effects such as flushing, hyper-
glycemia, gastrointestinal disturbance, and 
elevated liver enzymes interfered with adher-
ence to niacin treatment (66.3% of patients 
were adherent to treatment with niacin vs 
77.8% for placebo). The study was limited by 
the fact that flushing essentially unblinded 
participants and physicians. 
But adding niacin to a statin  
has no effect
A 2014 meta-analysis driven by the power of 
the large HPS2-Thrive study evaluated data 
from 35,301 patients primarily in second-
ary prevention trials.2,3 It found that adding 
niacin to statins had no effect on all-cause 
mortality, coronary heart disease mortality, 
nonfatal MI, or stroke. The subset of 6 trials 
(N=4991) assessing niacin monotherapy did 
show a reduction in cardiovascular events 
(odds ratio [OR]=0.62; confidence interval 
[CI], 0.54-0.82), whereas the 5 studies (30,310 
patients) involving niacin with a statin dem-
onstrated no effect (OR=0.94; CI, 0.83-1.06).
No benefit from niacin/statin therapy  
despite an improved lipid profile
A 2011 RCT included 3414 patients with coro-
nary heart disease on simvastatin who were 
randomized to niacin or placebo.4 All patients 
received simvastatin 40 to 80 mg ± ezetimibe 
10 mg/d to achieve low-density lipoprotein 
(LDL) cholesterol levels of 40 to 80 mg/dL.
At 3 years, no benefit was seen in the 
composite CVD primary endpoint (hazard 
ratio=1.02; 95% CI, 0.87-1.21; P=.79) even 
though the niacin group had significantly 
increased median high-density lipoprotein 
(HDL) cholesterol compared with placebo 
and lower triglycerides and LDL cholesterol 
compared with baseline. 
A nonsignificant trend toward increased 
stroke in the niacin group compared with 
placebo led to early termination of the study. 
However, multivariate analysis showed in-
dependent associations between ischemic 
stroke risk and age older than 65 years, his-
tory of stroke/transient ischemic attack/ca-
rotid artery disease, and elevated baseline 
cholesterol.6 
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Niacin combined with a statin  
increases the risk of adverse events
The largest RCT in the 2014 meta-analysis 
(HPS2-Thrive) evaluated 25,673 patients 
with established CVD receiving cholesterol- 
lowering therapy with simvastatin ± ezeti-
mibe who were randomized to niacin or 
placebo for a median follow-up period of 
3.9 years.3 A pre-randomization run-in phase 
established effective cholesterol-lowering 
therapy with simvastatin ± ezetimibe.
Niacin didn’t reduce the incidence of 
major vascular events even though, once 
again, it decreased LDL and increased HDL 
more than placebo. Niacin increased the risk 
of serious adverse events 56% vs 53% (risk 
ratio [RR]=6; 95% CI, 3-8; number needed 
to harm [NNH]=35; 95% CI, 25-60), such as 
new onset diabetes (5.7% vs 4.3%; P<.001; 
NNH=71) and gastrointestinal bleeding/- 
ulceration and other gastrointestinal disor-
ders (4.8% vs 3.8%; P<.001; NNH=100).
A subsequent 2014 study examined the 
adverse events recorded in the AIM-HIGH4 
TABLE
Niacin for CVD: What the studies show
Study type Population Intervention Comparison Outcome Comments
Meta-analysis 2
(11 studies)
35,301 patients 
in secondary  
prevention trials
Niacin alone or in 
combination with 
other cholesterol- 
lowering agents
Placebo or  
alternative  
cholesterol-  
lowering agent
No effect on:
1.  All-cause mortality 
(OR=1.02; 95% CI, 0.92-
1.15; P=.59)
2.  Coronary heart disease 
mortality (OR=0.93;  
95% CI, 0.76-1.12; P=.44)
3.  Nonfatal myocardial 
infarction (OR=0.85;  
95% CI, 0.72-1.01; P=0.07)
4.  Stroke (OR=0.96; 95% CI, 
0.75-1.22; P=.72)
RCT
HPS2-Thrive  
Collaborative 
Group3
25,673 patients 
ages 50-80 yrs 
with established 
CVD
Niacin/laropiprant 
2 g/40 mg daily, in 
combination with 
statin ± ezetimibe; 
median follow-up 
3.9 yrs
Placebo No effect on:
Major vascular events 
(13.2% vs 13.7%; rate  
ratio=0.96; 95% CI,  
0.90-1.03; P=.29)
•   Major coronary events 
(rate ratio=0.96;  
95% CI, 0.87-1.07; 
P=.51)
•   Stroke (rate ratio=1; 
95% CI, 0.88-1.13; 
P=.56)
Laropiprant,  
used to suppress  
flushing, may be a 
contributing  
variable to the  
adverse effects 
seen with this 
study
RCT
AIM-HIGH4
3414 patients 
ages ≥45 yrs with 
established CVD 
(85.2% male, 
92.2% white)
All patients were 
treated with  
statins and then  
randomized to  
niacin 1.5-2 g/d for 
36 mos or placebo
Placebo No effect on major CVD 
events:
16.4% vs 16.2% (HR=1.02; 
95% CI, 0.87-1.21; P=.79)
Study was  
discontinued early 
because of a trend 
toward increased 
ischemic stroke 
(HR=1.61; 95% CI, 
0.89-2.91; P=.11)
RCT
Coronary Drug 
Project1
8341 males ages 
30-64 yrs with 
definite EKG 
evidence of MI
Niacin 3 g/d Placebo Reduction in nonfatal MI 
(8.9% vs 12.2%; P=.002)
CI, confidence interval; CVD, coronary vascular disease; EKG, electrocardiogram; HR, hazard ratio; MI, myocardial infarction; OR, odds ratio. 
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study and found that niacin caused more 
gastrointestinal disorders (7.4% vs 5.5%; 
P=.02; NNH=53) and infections and infesta-
tions (8.1% vs 5.8%; P=.008; NNH=43) than 
placebo.7 The overall observed rate of seri-
ous hemorrhagic adverse events was low, 
however, showing no significant difference 
between the 2 groups (3.4% vs 2.9%; P=.36).
Recommendations
As of November 2013, the Institute for Clini-
cal Systems Improvement recommends 
against using niacin in combination with 
statins because of the increased risk of ad-
verse events without a reduction in CVD 
outcomes. Niacin may be considered as 
monotherapy in patients who can’t toler-
ate statins or fibrates based on results of 
the Coronary Drug Project and other stud-
ies completed before the era of widespread 
statin use.8 
Similarly, American College of Cardiol-
ogy/American Heart Association guidelines 
state that patients who are completely statin 
intolerant may use nonstatin cholesterol-
lowering drugs, including niacin, that have 
been shown to reduce CVD events in RCTs if 
the CVD risk-reduction benefits outweigh the 
potential for adverse effects.9               JFP
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